SYHA1801
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 08, 2020
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=186; Recruiting; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Monotherapy
March 17, 2020
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=186; Not yet recruiting; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Clinical • Monotherapy • New P1 trial
1 to 2
Of
2
Go to page
1